The next major value inflection point for Onxeo will likely be availability of Phase III Livatag data for second-line liver cancer expected H117. This product could potentially be the first launched by Onxeo in Europe as part of the orphan oncology strategy. Prior to Livatag data, progression with Beleodaq and Validive is expected, with the start of further Phase III trials anticipated in H116. Our valuation, which is largely unchanged at €328m, suggests the current share price is ascrib
08 Sep 2015
LA VIE est BELle (LivAtag, ValidIvE, BELeodaq)
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
LA VIE est BELle (LivAtag, ValidIvE, BELeodaq)
The next major value inflection point for Onxeo will likely be availability of Phase III Livatag data for second-line liver cancer expected H117. This product could potentially be the first launched by Onxeo in Europe as part of the orphan oncology strategy. Prior to Livatag data, progression with Beleodaq and Validive is expected, with the start of further Phase III trials anticipated in H116. Our valuation, which is largely unchanged at €328m, suggests the current share price is ascrib